Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews' Q3 Revenues, Net Loss Rise

NEW YORK (GenomeWeb News) – Biomarker test developer GeneNews has reported an increase in its third-quarter 2008 revenue to C$300,000 (US$246,000) from C$200,000 for last year’s third quarter.
 
The Toronto-based firm said that revenue in the most recent quarter came from a collaboration with an Asian biomedical consortium to identify and validate a set of biomarkers for prostate diseases. That deal was worth US$2 million to GeneNews. The firm’s Q3 2007 revenue came from a collaboration with Pfizer that has since been completed.
 
GeneNews posted a net loss of C$3.9 million, or C$.07 per share, compared to a net loss of C$3 million, or C$.05 per share, for the third quarter of 2007.
 
The company’s R&D costs increased around 8 percent to C$2.6 million from C$2.4 million, while its general and administrative spending was flat at C$700,000.
 
GeneNews finished the quarter with cash and cash equivalents of C$3.2 million.
 
The firm announced last week that it will cut 40 percent of its workforce in Canada as part of a restructuring effort. GeneNews said that its Canadian operations would focus on Canadian and US commercialization of its lead product, ColonSentry, a genomics-based test for determining a person’s risk for colorectal cancer. Meanwhile, its R&D activities, including patient sample accrual, will be moved to its operations in Asia.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.